Targeting the indirect antigen presentation pathway to prolong allograft survival
Transplanted organs are rejected via a number of antigen presentation pathways. The indirect pathway is thought to be responsible for chronic rejection for which there is no effective treatment. We aim to develop pharmacological agents that target this pathway in order to dampen the indirect presentation of antigens and thus, prevent chronic rejection of transplanted organs.